Loading…
Reported covered position: Legislative Assistant, Rep. Mike Ferguson
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · fourth_quarter · RA
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Source: Senate LDA
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA |
| 24 |
| 2017–2022 |
| ALIBABA GROUP HOLDING LIMITED | 23 | 2016–2021 |
| C.R. BARD INC. | 18 | 2016–2020 |
| CARDINAL HEALTH, INC. | 18 | 2018–2022 |
| INTEGRA LIFESCIENCES CORP. | 18 | 2016–2020 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 17 | 2017–2020 |
| AT&T SERVICES, INC. | 16 | 2023–2026 |
| CELGENE CORPORATION | 16 | 2016–2019 |
| GILEAD SCIENCES, INC. | 16 | 2016–2019 |
| IOWNIT CAPITAL AND MARKETS, INC. | 16 | 2019–2022 |
| ONCOSEC MEDICAL INC. | 16 | 2018–2022 |
| BIOIDENTICAL HORMONE REPLACEMENT THERAPY COALITION | 15 | 2019–2022 |
| GAMIDA | 15 | 2020–2024 |
| FERRING PHARMACEUTICALS, INC. | 14 | 2023–2026 |
| HILL-ROM HOLDINGS | 14 | 2019–2022 |
| STRONGBRIDGE BIOPHARMA PLC | 11 | 2018–2020 |
| UROGEN PHARMA LTD. | 11 | 2020–2022 |
| BECTON, DICKINSON AND COMPANY | 10 | 2020–2022 |
| GLOBAL AUTOMAKERS | 10 | 2017–2019 |
| CHILDREN'S HOSPITAL ASSOCIATION | 9 | 2017–2019 |
| EDGE THERAPEUTICS INC. | 9 | 2016–2018 |
| ADVAXIS, INC. | 8 | 2016–2017 |
| OPHTHOTECH CORP. | 8 | 2016–2017 |
| STRYKER CORPORATION | 8 | 2025–2026 |
| ARALEZ PHARMACEUTICALS US INC. | 7 | 2016–2017 |
| PRUDENTIAL FINANCIAL INC | 7 | 2016–2017 |
| SOUTHERN RESEARCH | 7 | 2023–2025 |
| BLACKBIRD LABORATORIES | 6 | 2025–2026 |
| GENENTECH INC | 6 | 2016–2017 |
| HEARING INDUSTRIES ASSOCIATION | 6 | 2025–2026 |
| INSMED INCORPORATED | 6 | 2018–2019 |
| BAXTER HEALTHCARE CORPORATION | 5 | 2022 |
| CORETSU INC. | 5 | 2025–2026 |
| OSRX, INC. | 5 | 2025–2026 |
| PROSPECT MEDICAL HOLDINGS, INC. | 5 | 2017 |
| TEXAS CHILDREN'S HOSPITAL | 5 | 2017 |
| THE FREEDOM INITIATIVE | 5 | 2022 |
| TYME TECHNOLOGIES, INC. | 5 | 2020 |
| AEROFLOW HEALTHCARE | 4 | 2017 |
| Pentec Health, Inc. | 4 | 2017 |
| Portola Pharmaceuticals, Inc. | 4 | 2017 |
| SQI DIAGNOSTICS | 4 | 2020–2021 |
| THE MEDICINES COMPANY | 4 | 2016 |
| WEBER-STEPHEN PRODUCTS LLC | 4 | 2020–2021 |
| DEPOMED INC | 3 | 2017 |
| ENGAGE CUBA | 3 | 2017 |
| SEMPRA ENERGY | 3 | 2022 |
| YAMO PHARMACEUTICALS, LLC | 3 | 2018 |
| CALIFORNIA WALNUT COMMISSION | 1 | 2022 |
| GOLDEN STATE NATURAL RESOURCES, INC. | 1 | 2021 |
| GOLDEN VALLEY ELECTRIC ASSOCIATION | 1 | 2022 |
| HEXIUM INC. | 1 | 2026 |
| IRANIAN AMERICAN COMMUNITY OF NORTHERN CALIFORNIA | 1 | 2022 |
| NATIONAL HEALTHY START ASSOCIATION | 1 | 2022 |
| RIPPLE LABS, INC. | 1 | 2017 |
| STRATEGIES 360 |
| 1 |
| 2022 |
| TOWNSEND PUBLIC AFFAIRS, INC | 1 | 2021 |
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.
Client: BAXTER HEALTHCARE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Medicare Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Further Consolidated Appropriations Act, 2020
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Further Consolidated Appropriations Act, 2020
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Lower Costs, More Cures Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.69, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S. 692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. S.692, the Protect Medical Innovation Act. H.R. 2207, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2207, the Protect Medical Innovation Act. S. 692, the Protect Medical Innovation Act.
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: CARDINAL HEALTH, INC. · Firm: BAKER & HOSTETLER LLP
S.692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
Protect Medical Innovation Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
S. 692, the Protect Medical Innovation Act H.R. 2207, the Protect Medical Innovation Act
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting.
More Efficient Tools to Realize Information for Consumers Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
More Efficient Tools to Realize Information for Consumers Act
Client: C.R. BARD INC. · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid; H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting; H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Contact Lens Prescription Verification Modernization Act
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Diabetic Vision Loss and Blindness Prevention Act of 2019
Client: HILL-ROM HOLDINGS · Firm: BAKER & HOSTETLER LLP
Medicare coverage for medical technology. H.R. 5254, the Diabetic Vision Loss and Blindness Prevention Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 1730, the "Cancer Drug Parity Act". S. 741, the "Cancer Drug Parity Act". H.R. 985, the "FAST Generics Act". S. 340, the "CREATES Act". H.R. 965, the "CREATES Act".
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R.1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Clean Water Through Green Infrastructure Act
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act. H.R. 1865, the Further Consolidated Appropriations Act, 2020, specifically Section 501, repeal of the medical device excise tax. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3975, the Contact Lens Prescription Verification Modernization Act. H.R. 3762, the Dental and Optometric Care Access Act. H.R. 4665, the Medicare Vision Act. S. 1423, the Medicare and Medicaid Dental, Vision, and Hearing Benefit Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Prescription Drug Pricing Reduction Act of 2019
Client: ALCON VISION LLC · Firm: BAKER & HOSTETLER LLP
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act, including medical device product samples reporting. H.R. 2296, the FAIR Drug Pricing Act, including medical device product samples reporting. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. H.R. 3, the Lower Drug Costs Now Act. H.R. 19, the Lower Costs, More Cures Act. S. 2543, the Prescription Drug Price Reduction Act. S. 3129, the Lower Costs, More Cures Act.
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · 3T
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
CORETSU INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2026 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEXIUM INC. via BAKER & HOSTETLER LLP
2026 · first_quarter · RR
Federal energy, national security, and research policy related to advanced isotope enrichment technologies and nuclear fuel cycle.
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
CORETSU INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Artificial intelligence and technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX, INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · RR
Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.
CORETSU INC. via BAKER & HOSTETLER LLP
2025 · fourth_quarter · RR
Artificial intelligence and technology policy issues.
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · 3A
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
HEARING INDUSTRIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · third_quarter · RR
Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.
BLACKBIRD LABORATORIES via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies related to biotech research and laboratory testing models.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to medical devices and technologies.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2025 · first_quarter · 1T
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2025 · first_quarter · Q1
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BAKER & HOSTETLER LLP
2025 · first_quarter · RA
Federal regulatory and reimbursement issues relating to medical technologies and devices.
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALCON VISION LLC via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE, INC. via BAKER & HOSTETLER LLP
2024 · fourth_quarter · Q4
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
ALCON VISION LLC via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Federal regulatory and reimbursement policies relating to eye care services, medicines and medical technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2024 · third_quarter · Q3
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
SOUTHERN RESEARCH via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Policy issues regarding healthcare research, including federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OUTSOURCING FACILITIES ASSOCIATION via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Policy issues related to outsourcing facilities as defined under Sec. 503B of Public Law No. 113-54, the Drug Quality and Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASDAQ, INC. via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
FERRING PHARMACEUTICALS, INC. via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy and oncology treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUITY MARKETS ASSOCIATION via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that affect national securities exchange liability, immunity and governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
AT&T SERVICES, INC. via BAKER & HOSTETLER LLP
2024 · second_quarter · Q2
Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE